Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astex Pharmaceuticals Inc.

Division of Astex Pharmaceuticals Inc./Montigen Pharmaceuticals Inc.
astx.com

Latest From Astex Pharmaceuticals Inc.

Merck Joins KRAS Stampede In Deal With Otsuka Affiliates

Merck & Co. is paying $50m up front to combine preclinical KRAS-target cancer compound pipelines with Astex and Taiho, both affiliates of Japan’s Otsuka. The two biotechs could realize up to $2.5bn in earnouts under the collaboration.

Deals Research and Development Strategies

Asia Deal Watch: Everest Licenses Asia Rights To Calliditas’ IgA Nephropathy Candidate

While an orphan indication in the US and EU, IgAN accounts for 40% of glomerular disease in China; deal also confers rights in Hong Kong, Macau, Taiwan, Singapore. Also, Y-Biologics teams with Dualogics on bispecific antibodies for cancer.

Business Strategies Deals

Astex Eyes First Filing For Oral Decitabine On Positive Combo Results

Otsuka subsidiary Astex plans filing in MDS by year-end for first oral decitabine product on the back of positive Phase III comparative results.

Cancer Clinical Trials

Biotech CEOs: Can Scientist-Founders Remain In Charge?

Founder-CEOs do not typically remain at the helm as biotechs mature. Exceptions to that rule are multiplying, though, especially in Europe as companies aim directly for Nasdaq.

C-Suite Speaks Business Strategies
See All

Company Information

UsernamePublicRestriction

Register